Filter By Industry
Filter By Tag

Newsroom

NAPSRx Press releases

51 - 60 of 357 Press Releases

Jan 22, 2015
The US Food and Drug Administration (FDA) has approved Novartis’ new psoriasis treatment Cosentyx (secukinumab) for adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the...

Jan 21, 2015
Johnson and Johnson (J & J) reported strong sales for its pharmaceutical business segment with worldwide revenue amounting to $32.3 billion for the full-year 2014,  which is a 14.9% increase compared to 2013.

Jan 19, 2015
UCB has entered into a deal with Neuropore Therapies Inc to develop and commercialize therapeutics to slow the progression of Parkinson’s disease and related disorders.

Jan 15, 2015
Certified National Pharmaceutical Representatives (CNPR) are individuals who have gone through the comprehensive CNPR Certification Program to further broaden their skill set and acquire the necessary industry training for an exciting career in...

Jan 14, 2015
Janssen Biotech a division of Johnson & Johnson ( J & J) will pay $241 million for Vedanta Bioscience’s mix of bacteria from the Clostridia subspecies that could potentially treat Crohn’s disease and ulcerative colitis.

Jan 12, 2015
Shire will acquire NPS Pharmaceuticals for $46.00 per share in cash amounting to approximately $5.2 billion. The acquisition will give Shire access to NPS Pharma’s gastrointestinal (GI) disorders portfolio and rare disease pipeline.

Jan 09, 2015
SAVAYSA™ (edoxaban) tablets, an oral once-daily selective factor Xa-inhibitor have been approved by the U.S.

Jan 07, 2015
The U.S. Food and Drug Administration has approved Suneva Medical’s dermal filler Bellafill® to treat acne scars.

Jan 06, 2015
Amgen and Kite Pharma will join forces to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies.

Jan 05, 2015
Bristol-Myers Squibb Company (NYSE:BMY) and the California Institute for Biomedical Research (Calibr) have announced their plans to collaborate on research and development for small molecule anti-fibrotic treatments.


Page: Prev 4 5 6 7 8 Next
NAPSRx RSS Feed